Hub : Traits :

Medication: Atorvastatin

56 significantly associated models · 27 unique genes.

Significant Loci

#	chr	p0	p1	# assoc genes	# joint genes	best TWAS P	best SNP P	cond SNP P	% var exp	joint genes
1	1	108854166	110733794	6	1	3.8e-29	6.6e-29	1.0e+00	100	PSRC1
2	2	20529948	21958745	1	1	4.7e-12	2.1e-12	1.0e+00	100	APOB
3	2	26854065	28414302	5	1	2.1e-14	3.1e-14	1.0e+00	100	FNDC4
4	5	73969058	75594743	4	1	1.0e-14	2.1e-12	7.5e-01	100	HMGCR
5	9	21303958	22705094	1	1	2.7e-07	9.2e-10	1.4e-04	61	CDKN2B
6	11	115953897	117745003	3	4	4.0e-20	1.3e-22	2.0e-07	72	BUD13 PAFAH1B2 ZNF259
7	19	10377885	12191233	4	3	1.7e-09	2.4e-29	9.8e-18	42	EPOR KANK2 SPC24
8	19	44704753	46098885	2	2	3.9e-08	4.9e-36	1.2e-28	22	PVRL2 TOMM40

Pleiotropic Associations

Trait	chisq ratio	# genes⁺	# genes⁺⁺	% genes⁺⁺	corr	corr P	genes
Bipolar Disorder (2018)	1.83	1	0	0.0	0.00	1.0e+00	FNDC4
Schizophrenia vs Biploar Disorder	1.44	1	0	0.0	0.00	1.0e+00	FNDC4
Alzheimer’s Disease (in mother)	10.08	2	2	4.4	0.00	1.0e+00	PVRL2 TOMM40
Alzheimer’s Disease (in father)	4.50	2	1	2.2	0.00	1.0e+00	PVRL2 TOMM40
Alzheimer’s Disease (including proxy)	19.19	2	2	4.4	0.00	1.0e+00	PVRL2 TOMM40
Crohns Disease (2017)	2.08	1	1	2.2	0.00	1.0e+00	FNDC4
Irritable Bowel Disease (IBD)	1.71	1	1	2.2	0.00	1.0e+00	FNDC4
Breast Cancer	1.61	1	0	0.0	0.00	1.0e+00	CDKN2B
Body Mass Index (BMI) (2010)	1.65	1	0	0.0	0.00	1.0e+00	HMGCR
Coronary Artery Disease (CAD)	17.23	5	3	6.7	0.94	5.1e-03	BUD13 CDKN2B EPOR PSRC1 ZNF259
Crohns Disease (2012)	0.96	1	0	0.0	0.00	1.0e+00	FNDC4
Fasting Glucose	7.78	1	1	2.2	0.00	1.0e+00	FNDC4
HDL Cholesterol	22.84	6	3	6.7	-0.67	9.7e-02	APOB BUD13 PSRC1 PVRL2 TOMM40 ZNF259
LDL Cholesterol	121.82	12	11	24.4	0.88	7.1e-05	APOB BUD13 EPOR FNDC4 HMGCR KANK2 PAFAH1B2 PSRC1 PVRL2 SPC24 TOMM40 ZNF259
Primary Biliary Cirrhosis	2.16	2	0	0.0	0.00	1.0e+00	EPOR FNDC4
Rheumatoid Arthritis	1.71	1	0	0.0	0.00	1.0e+00	KANK2
Triglycerides	110.39	6	5	11.1	0.58	1.8e-01	APOB BUD13 FNDC4 PAFAH1B2 PVRL2 ZNF259
Type 2 Diabetes (T2D) (2012)	2.01	1	0	0.0	0.00	1.0e+00	CDKN2B
Ulcerative Colitis	1.38	1	0	0.0	0.00	1.0e+00	PAFAH1B2
Blood Eosinophil Count	2.55	5	3	6.7	-0.19	7.2e-01	BUD13 EPOR PAFAH1B2 TOMM40 ZNF259
Blood Platelet Count	6.49	8	6	13.3	-0.02	9.6e-01	BUD13 CDKN2B FNDC4 HMGCR PAFAH1B2 PVRL2 TOMM40 ZNF259
Blood Red Count	0.86	2	1	2.2	0.00	1.0e+00	FNDC4 PVRL2
Blood White Count	3.46	6	2	4.4	0.16	7.6e-01	CDKN2B EPOR FNDC4 KANK2 PAFAH1B2 PVRL2
Heel T-Score	0.79	4	0	0.0	-0.74	2.6e-01	APOB HMGCR PSRC1 TOMM40
BMI	2.33	3	2	4.4	0.00	1.0e+00	FNDC4 HMGCR KANK2
Height	1.74	7	5	11.1	-0.88	3.6e-03	EPOR FNDC4 KANK2 PSRC1 SPC24 TOMM40 ZNF259
Waist Hip Ratio (WHR)	0.87	1	0	0.0	0.00	1.0e+00	KANK2
Systolic Blood Pressure	1.41	4	0	0.0	0.99	6.9e-03	EPOR FNDC4 PAFAH1B2 TOMM40
Allergy or Eczema	1.53	2	0	0.0	0.00	1.0e+00	FNDC4 PVRL2
Cardiovascular Disease	13.79	11	11	24.4	0.99	4.0e-09	APOB BUD13 EPOR FNDC4 HMGCR PAFAH1B2 PSRC1 PVRL2 SPC24 TOMM40 ZNF259
Type 2 Diabetes (T2D) (2018)	4.05	1	1	2.2	0.00	1.0e+00	FNDC4
Lung FEV1/FVC ratio	1.03	1	1	2.2	0.00	1.0e+00	PSRC1
Lung FVC	0.87	2	0	0.0	0.00	1.0e+00	FNDC4 PVRL2
Hair Pigment	0.38	3	1	2.2	0.00	1.0e+00	CDKN2B EPOR FNDC4
Tanning	0.42	2	1	2.2	0.00	1.0e+00	EPOR FNDC4
Hand grip strength (left)	1.35	2	0	0.0	0.00	1.0e+00	FNDC4 PVRL2
Number of treatments/medications taken	4.64	2	0	0.0	0.00	1.0e+00	FNDC4 PSRC1
Relative age of first facial hair	1.96	1	1	2.2	0.00	1.0e+00	FNDC4
Systolic blood pressure, automated reading	0.81	1	0	0.0	0.00	1.0e+00	EPOR
Angina	12.37	3	2	4.4	0.00	1.0e+00	CDKN2B PSRC1 SPC24
Medication: Metformin	2.82	2	1	2.2	0.00	1.0e+00	CDKN2B FNDC4
Diabetes (father)	2.80	1	0	0.0	0.00	1.0e+00	FNDC4
Diabetes (mother)	2.94	2	0	0.0	0.00	1.0e+00	FNDC4 PVRL2
Impedance of leg (right)	2.23	2	2	4.4	0.00	1.0e+00	FNDC4 HMGCR
Leg fat-free mass (left)	3.59	5	2	4.4	-0.85	7.1e-02	EPOR FNDC4 HMGCR PSRC1 SPC24
Trunk fat percentage	1.37	2	1	2.2	0.00	1.0e+00	HMGCR PVRL2
Hand grip strength (right)	1.39	2	0	0.0	0.00	1.0e+00	FNDC4 PVRL2
Hayfever, allergic rhinitis or eczema	1.61	2	0	0.0	0.00	1.0e+00	FNDC4 PVRL2
Sitting height	1.69	3	1	2.2	0.00	1.0e+00	FNDC4 KANK2 SPC24
Body mass index (BMI)	2.08	3	1	2.2	0.00	1.0e+00	FNDC4 HMGCR PVRL2
Impedance of leg (left)	2.24	2	2	4.4	0.00	1.0e+00	FNDC4 HMGCR
Leg predicted mass (left)	3.59	5	2	4.4	-0.85	6.9e-02	EPOR FNDC4 HMGCR PSRC1 SPC24
Trunk fat mass	1.67	2	1	2.2	0.00	1.0e+00	HMGCR PVRL2
Waist circumference	1.87	3	1	2.2	0.00	1.0e+00	FNDC4 HMGCR PVRL2
Forced vital capacity (FVC)	1.02	2	0	0.0	0.00	1.0e+00	EPOR PVRL2
Heart attack	9.12	3	2	4.4	0.00	1.0e+00	CDKN2B PSRC1 SPC24
Diabetes (self-reported)	3.07	1	1	2.2	0.00	1.0e+00	FNDC4
Medication: Simvastatin	35.22	12	10	22.2	0.97	1.6e-08	APOB BUD13 CDKN2B EPOR FNDC4 HMGCR PAFAH1B2 PSRC1 PVRL2 SPC24 TOMM40 ZNF259
Weight	2.77	4	2	4.4	-0.99	1.4e-02	EPOR FNDC4 HMGCR PVRL2
Impedance of arm (right)	3.30	4	2	4.4	0.84	1.6e-01	CDKN2B FNDC4 HMGCR KANK2
Arm fat percentage (right)	1.45	2	1	2.2	0.00	1.0e+00	HMGCR PVRL2
Trunk fat-free mass	4.34	5	4	8.9	-0.84	7.3e-02	EPOR FNDC4 HMGCR PSRC1 SPC24
Hip circumference	2.11	3	2	4.4	0.00	1.0e+00	FNDC4 HMGCR PVRL2
Alcohol intake versus 10 years previously	2.91	1	1	2.2	0.00	1.0e+00	FNDC4
Father's age at death	4.07	2	0	0.0	0.00	1.0e+00	CDKN2B PSRC1
Forced expiratory volume in 1-second (FEV1)	1.21	2	0	0.0	0.00	1.0e+00	EPOR PVRL2
Pulse rate	3.28	1	1	2.2	0.00	1.0e+00	FNDC4
Mouth/teeth dental problems: Dentures	1.27	1	0	0.0	0.00	1.0e+00	FNDC4
Medication: Cholesterol lowering	46.53	13	11	24.4	0.99	7.3e-11	APOB BUD13 CDKN2B EPOR FNDC4 HMGCR KANK2 PAFAH1B2 PSRC1 PVRL2 SPC24 TOMM40 ZNF259
Illnesses of mother	1.93	1	0	0.0	0.00	1.0e+00	CDKN2B
Forced expiratory volume in 1-second (FEV1), Best measure	1.28	2	0	0.0	0.00	1.0e+00	EPOR PVRL2
Impedance of arm (left)	3.38	3	2	4.4	0.00	1.0e+00	FNDC4 HMGCR KANK2
Arm fat mass (right)	2.03	3	1	2.2	0.00	1.0e+00	FNDC4 HMGCR PVRL2
Trunk predicted mass	4.37	5	4	8.9	-0.84	7.3e-02	EPOR FNDC4 HMGCR PSRC1 SPC24
Standing height	1.91	5	4	8.9	-0.91	3.0e-02	EPOR FNDC4 KANK2 PSRC1 SPC24
Birth weight of first child	1.53	1	0	0.0	0.00	1.0e+00	EPOR
Peak expiratory flow (PEF)	0.92	1	0	0.0	0.00	1.0e+00	EPOR
Medication for cholesterol, blood pressure or diabetes	17.60	11	6	13.3	-0.98	9.0e-09	APOB BUD13 EPOR FNDC4 HMGCR PAFAH1B2 PSRC1 PVRL2 SPC24 TOMM40 ZNF259
Glaucoma (self-reported)	3.91	1	1	2.2	0.00	1.0e+00	CDKN2B
Gout (self-reported)	8.47	1	1	2.2	0.00	1.0e+00	FNDC4
High blood pressure (siblings)	1.67	1	0	0.0	0.00	1.0e+00	FNDC4
Forced vital capacity (FVC), Best measure	1.20	2	0	0.0	0.00	1.0e+00	EPOR PVRL2
Body fat percentage	1.56	2	1	2.2	0.00	1.0e+00	HMGCR PVRL2
Leg fat percentage (right)	1.70	3	1	2.2	0.00	1.0e+00	HMGCR KANK2 PVRL2
Arm fat-free mass (right)	4.19	4	2	4.4	-0.81	1.9e-01	EPOR FNDC4 HMGCR PSRC1
Comparative body size at age 10	1.05	1	0	0.0	0.00	1.0e+00	FNDC4
Number of full brothers	1.66	1	0	0.0	0.00	1.0e+00	ZNF259
Qualifications: College or University degree	0.72	1	0	0.0	0.00	1.0e+00	BUD13
Angina (self-reported)	12.35	3	2	4.4	0.00	1.0e+00	CDKN2B PSRC1 SPC24
Medication: Allopurinol	6.69	1	1	2.2	0.00	1.0e+00	FNDC4
Heart disease (mother)	5.83	1	1	2.2	0.00	1.0e+00	CDKN2B
Whole body fat mass	1.82	3	1	2.2	0.00	1.0e+00	FNDC4 HMGCR PVRL2
Leg fat mass (right)	2.12	3	1	2.2	0.00	1.0e+00	FNDC4 HMGCR PVRL2
Arm predicted mass (right)	4.13	4	2	4.4	-0.81	1.9e-01	EPOR FNDC4 HMGCR PSRC1
Pulse rate, automated reading	4.24	3	1	2.2	0.00	1.0e+00	APOB FNDC4 KANK2
Alcohol intake frequency.	5.86	1	1	2.2	0.00	1.0e+00	FNDC4
Comparative height size at age 10	2.55	4	2	4.4	-0.90	9.6e-02	FNDC4 KANK2 PSRC1 SPC24
Chest pain or discomfort	1.43	1	0	0.0	0.00	1.0e+00	CDKN2B
Medication: Aspirin	9.32	5	2	4.4	0.97	5.4e-03	APOB CDKN2B EPOR PSRC1 SPC24
Illnesses of father: Heart disease	11.14	5	2	4.4	0.94	1.8e-02	CDKN2B EPOR FNDC4 PSRC1 SPC24
Forced expiratory volume in 1-second (FEV1), predicted	1.61	1	0	0.0	0.00	1.0e+00	EPOR
Whole body fat-free mass	4.19	5	3	6.7	-0.85	7.0e-02	EPOR FNDC4 HMGCR PSRC1 SPC24
Leg fat-free mass (right)	3.61	5	2	4.4	-0.86	6.5e-02	EPOR FNDC4 HMGCR PSRC1 SPC24
Arm fat percentage (left)	1.44	2	1	2.2	0.00	1.0e+00	HMGCR PVRL2
Long-standing illness, disability or infirmity	2.08	1	0	0.0	0.00	1.0e+00	CDKN2B
Diabetes diagnosed by doctor	3.41	1	1	2.2	0.00	1.0e+00	FNDC4
Medication for cholesterol	7.72	6	1	2.2	-0.98	7.2e-04	FNDC4 HMGCR PAFAH1B2 PSRC1 PVRL2 SPC24
Back pain experienced in last month	1.62	1	0	0.0	0.00	1.0e+00	APOB
Breast cancer (self-reported)	1.56	1	0	0.0	0.00	1.0e+00	CDKN2B
Osteoporosis (self-reported)	1.53	1	0	0.0	0.00	1.0e+00	FNDC4
Medication: Aspirin	9.27	4	2	4.4	0.97	2.8e-02	CDKN2B EPOR PSRC1 SPC24
Medication: Gliclazide	2.63	1	0	0.0	0.00	1.0e+00	FNDC4
Illnesses of father: None of the above (group 1)	3.81	1	1	2.2	0.00	1.0e+00	CDKN2B
Forced expiratory volume in 1-second (FEV1), predicted percentage	1.26	1	0	0.0	0.00	1.0e+00	PVRL2
Whole body water mass	4.22	5	2	4.4	-0.84	7.4e-02	EPOR FNDC4 HMGCR PSRC1 SPC24
Leg predicted mass (right)	3.61	5	2	4.4	-0.85	6.5e-02	EPOR FNDC4 HMGCR PSRC1 SPC24
Arm fat mass (left)	1.99	3	1	2.2	0.00	1.0e+00	FNDC4 HMGCR PVRL2
Number of self-reported non-cancer illnesses	4.65	2	1	2.2	0.00	1.0e+00	FNDC4 PSRC1
Eye problems/disorders: Glaucoma	4.58	1	1	2.2	0.00	1.0e+00	CDKN2B
High cholesterol (Self-reported)	84.07	12	12	26.7	0.98	3.9e-09	APOB BUD13 EPOR FNDC4 HMGCR KANK2 PAFAH1B2 PSRC1 PVRL2 SPC24 TOMM40 ZNF259
Basal metabolic rate	3.87	5	2	4.4	-0.85	6.9e-02	EPOR FNDC4 HMGCR PSRC1 SPC24
Leg fat percentage (left)	1.73	3	1	2.2	0.00	1.0e+00	HMGCR KANK2 PVRL2
Arm fat-free mass (left)	4.02	4	2	4.4	-0.81	1.9e-01	EPOR FNDC4 HMGCR PSRC1
Diastolic blood pressure, automated reading	1.17	1	0	0.0	0.00	1.0e+00	CDKN2B
Myopia	2.11	1	0	0.0	0.00	1.0e+00	KANK2
Cholesterol lowering medication	42.47	13	12	26.7	0.99	5.7e-11	APOB BUD13 CDKN2B EPOR FNDC4 HMGCR KANK2 PAFAH1B2 PSRC1 PVRL2 SPC24 TOMM40 ZNF259
Pain experienced in last month	1.15	1	0	0.0	0.00	1.0e+00	APOB
Basal cell carcinoma (self-reported)	2.03	1	0	0.0	0.00	1.0e+00	CDKN2B
Heart attack/myocardial infarction (self-reported)	9.24	3	2	4.4	0.00	1.0e+00	CDKN2B PSRC1 SPC24
Heart disease (siblings)	5.05	2	0	0.0	0.00	1.0e+00	PSRC1 ZNF259
Impedance of whole body	3.12	3	2	4.4	0.00	1.0e+00	FNDC4 HMGCR PSRC1
Leg fat mass (left)	2.14	3	1	2.2	0.00	1.0e+00	FNDC4 HMGCR PVRL2
Arm predicted mass (left)	4.13	4	2	4.4	-0.82	1.8e-01	EPOR FNDC4 HMGCR PSRC1

Associations by panel

study	tissue	# hits	% hits/tests	avg chisq
GTEx	Adipose Subcutaneous	1	0.029	1.2
GTEx	Adipose Visceral Omentum	0	0.000	1.3
GTEx	Adrenal Gland	0	0.000	1.2
GTEx	Artery Aorta	0	0.000	1.3
GTEx	Artery Coronary	0	0.000	1.2
GTEx	Artery Tibial	0	0.000	1.3
GTEx	Brain Caudate basal ganglia	0	0.000	1.1
GTEx	Brain Cerebellar Hemisphere	0	0.000	1.3
GTEx	Brain Cerebellum	0	0.000	1.3
GTEx	Brain Cortex	0	0.000	1.2
GTEx	Brain Frontal Cortex BA9	0	0.000	1.2
GTEx	Brain Hippocampus	0	0.000	1.1
GTEx	Brain Hypothalamus	0	0.000	1.2
GTEx	Brain Nucleus accumbens basal ganglia	0	0.000	1.1
GTEx	Brain Putamen basal ganglia	0	0.000	1.1
GTEx	Breast Mammary Tissue	0	0.000	1.2
GTEx	Breast Mammary Tissue (Male)	0	0.000	1.2
GTEx	Breast Mammary Tissue (Female)	0	0.000	1.2
GTEx	Cells EBV-transformed lymphocytes	0	0.000	1.2
GTEx	Cells Transformed fibroblasts	2	0.048	1.3
GTEx	Colon Sigmoid	0	0.000	1.2
GTEx	Colon Transverse	0	0.000	1.3
GTEx	Esophagus Gastroesophageal Junction	0	0.000	1.2
GTEx	Esophagus Mucosa	3	0.090	1.3
GTEx	Esophagus Muscularis	1	0.031	1.2
GTEx	Heart Atrial Appendage	0	0.000	1.2
GTEx	Heart Left Ventricle	0	0.000	1.2
GTEx	Liver	2	0.279	1.5
GTEx	Lung	0	0.000	1.2
GTEx	Muscle Skeletal	1	0.035	1.3
GTEx	Nerve Tibial	0	0.000	1.2
GTEx	Ovary	1	0.110	1.4
GTEx	Pancreas	0	0.000	1.2
GTEx	Pituitary	0	0.000	1.3
GTEx	Prostate	0	0.000	1.2
GTEx	Skin Not Sun Exposed Suprapubic	0	0.000	1.2
GTEx	Skin Sun Exposed Lower leg	1	0.027	1.3
GTEx	Small Intestine Terminal Ileum	0	0.000	1.2
GTEx	Spleen	1	0.071	1.3
GTEx	Stomach	0	0.000	1.3
GTEx	Testis	2	0.063	1.2
GTEx	Thyroid	2	0.050	1.3
GTEx	Uterus	0	0.000	1.2
GTEx	Vagina	1	0.157	1.2
GTEx	Whole Blood	1	0.050	1.4
METSIM	Adipose	1	0.022	1.2
NTR	Blood	1	0.042	1.3
ROSMAP	Brain Pre-frontal Cortex	2	0.046	1.3
YFS	Blood	2	0.043	1.3
CommonMind	Brain Pre-frontal Cortex	7	0.130	1.3
The Cancer Genome Atlas	Bladder Urothelial Carcinoma	0	0.000	1.3
The Cancer Genome Atlas	Breast Invasive Carcinoma	2	0.045	1.2
The Cancer Genome Atlas	Cervical Squamous Cell Carcinoma	1	0.091	1.3
The Cancer Genome Atlas	Colon Adenocarcinoma	2	0.097	1.3
The Cancer Genome Atlas	Esophageal Carcinoma	0	0.000	1.2
The Cancer Genome Atlas	Glioblastoma Multiforme	1	0.098	1.2
The Cancer Genome Atlas	Head and Neck Squamous Cell Carcinoma	0	0.000	1.2
The Cancer Genome Atlas	Kidney Renal Clear Cell Carcinoma	1	0.024	1.2
The Cancer Genome Atlas	Kidney Renal Papillary Cell Carcinoma	2	0.098	1.3
The Cancer Genome Atlas	Brain Lower Grade Glioma	1	0.023	1.3
The Cancer Genome Atlas	Liver Hepatocellular Carcinoma	3	0.271	1.4
The Cancer Genome Atlas	Lung Adenocarcinoma	0	0.000	1.2
The Cancer Genome Atlas	Lung Squamous Cell Carcinoma	1	0.040	1.2
The Cancer Genome Atlas	Ovarian Serous Cystadenocarcinoma	3	0.188	1.2
The Cancer Genome Atlas	Pancreatic Adenocarcinoma	0	0.000	1.2
The Cancer Genome Atlas	Pheochromocytoma and Paraganglioma	0	0.000	1.2
The Cancer Genome Atlas	Prostate Adenocarcinoma	2	0.043	1.3
The Cancer Genome Atlas	Rectum Adenocarcinoma	0	0.000	1.3
The Cancer Genome Atlas	Soft Tissue Sarcoma	1	0.094	1.2
The Cancer Genome Atlas	Skin Cutaneous Melanoma	0	0.000	1.2
The Cancer Genome Atlas	Stomach Adenocarcinoma	2	0.119	1.2
The Cancer Genome Atlas	Testicular Germ Cell Tumors	0	0.000	1.2
The Cancer Genome Atlas	Thyroid Carcinoma	2	0.039	1.2
The Cancer Genome Atlas	Uterine Corpus Endometrial Carcinoma	0	0.000	1.1